News Highlights

News about and goings on at FUSION GENOMICS:

Fusion Genomics Receives $1 Million from CQDM To Study ONETest RTI Assay

We are pleased to share the news that Fusion Genomics has received a $1 million award to conduct a study evaluating our comprehensive, novel ONETest PathoGenome assay for the detection of pathogens associated with respiratory tract infections (RTIs). Due in great part to limitations associated with current diagnostic tests, RTIs are a leading cause of morbidity, mortality, and hospitalizations globally. Faster identification and diagnosis of pathogens responsible for these infections could help reduce their tremendous burden on patients and hospitals.

We are honored by CQDM’s decision to include the ONETest RTI assay among its prestigious portfolio of funded programs. The prospective clinical study, which we will conduct in partnership with Sunnybrook Research Institute, could help to transform the diagnosis and treatment of RTIs.

For more information, click here to read the news release we distributed this morning, and please don’t hesitate to contact us if you have any questions regarding this exciting new project.

Fusion Connects with China!

C2 iBridge interview with Fusion’s Mohammad Qadir

Fusion’s CSO, Dr Mohammad Qadir recently attended the Canada China Innovation & Investment Summit 2019 put together by C2CAN. Dr Qadir was recently interviewed in their September 2019 newsletter starting on page 6.

As the key organizer of the summit, C2CAN is a collaborative platform between SFU VentureLabsⓇ, China Canada Cleantech Innovation Centre (CCCIC), Tsinghua Holdings, and Hanhai Holdings. Its mission is to connect technology companies with the resources necessary to scale and succeed in China and Canada.

From the C2 iBridge website:

Through its new Canada China Innovation Bridge program (C2 iBridge), C2CAN aims to further its mission to promote cross-border collaboration in science and technology innovation between Canada and China.

​C2 Innovation & Investment Bridge (C2 iBridge) is a C2CAN program that focuses exclusively on events that support the C2CAN mission.

Fusion is looking to hire a Postdoctoral Fellow

FUSION GENOMICS Corporation is a molecular diagnostic company that develops clinical assays using next-generation sequencing technologies to characterize infectious disease agents of clinical and global importance. We are looking to hire a full-time Postdoctoral Fellow to join our team in an exciting and highly dynamic start-up environment.  

FUSION GENOMICS is looking for a passionate, self driven, team player to join our team.

The position will involve working directly with the upper management to write technical documents, grants, and white papers. The job will involve in depth literature review, review of next generation sequencing data, and writing of technical and white papers to be used internally, distributed to collaborators, scientific conferences, and marketing.

The successful candidate has demonstrable experience in:

  • creating technical documents
  • grant writing
  • data analysis
  • creating white papers

The successful candidate requires comprehensive knowledge of:

  • Genomics
  • Next Generation Sequencing
  • Infectious Disease Biology

Requirements

  • Completed your PhD within the last 2 years
  • A canadian citizen, permanent resident, or international student

How to Apply

Please submit a cover letter and your CV featuring your top 3-5 publications to: jobs@fusiongenomics.com

Location: Vancouver, Lower Mainland

FUSION GENOMICS is located at SFU Venture Labs in Discovery Park on the main SFU campus in Burnaby, BC. We offer a highly competitive compensation package that includes a base salary and health benefits. Combine that with the opportunity and challenge to develop your career and to experience FUSION as a great fit for your next career move.